EU Directive Overrides French Law

26 March 1995

France's Supreme Court of Appeal has set aside the application of a French regulation restricting cosmetics imports in favor of a European Union directive. legal experts say the ruling is significant for all sectors of the economy, especially pharmaceuticals.

The director of a Dutch firm marketing cosmetics imported from the Netherlands was fined by a Versailles appeal court for having "opened and exploited" a cosmetics import company without having notified the administration or indicated the qualifications and standing of the person responsible for product control, and putting products on the market without having submitted a dossier containing details of their composition. the case went to a further appeal and the director claimed the French rule was more restrictive than the relevant EU directive of July 1976.

It was noted that the European Court of Justice had censured France in May 1993 for failing to respect the 1976 directive, which states that placing cosmetics on the market is subject to provision of adequate and sufficient information about the substances they contain, to permit rapid medical treatment if the user experiences problems. But while the Versailles court argued that the French rule was justified because it was concerned with protecting health and life, the Supreme Court of Appeal said this argument could only be accepted in the absence of an EU directive. The Supreme Court added that the 1976 directive involved exhaustive harmonization of the rules applicable to cosmetics.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight